Stephen Boorjian, MD, discusses the efficacy results of the phase II study intravesical nadofaragene firadenovec in patients with high-grade, Bacillus Calmette-Guerin unresponsive nonmuscle invasive bladder cancer, which he presented at the 2020 Genitourinary Cancer Symposium.
Stephen Boorjian, MD, professor of Urology, Mayo Clinic, discusses the efficacy results of the phase III study intravesical nadofaragene firadenovec (Instilladrin) in patients with high-grade, Bacillus Calmette-Guerin unresponsive nonmuscle invasive bladder cancer (NMIBC), which he presented at the 2020 Genitourinary Cancer Symposium.
The primary finding from the study was that 53% of patients with carcinoma in situ achieved a complete response following treatment with nadofaragene firadenovec, meeting the primary end point of the study.
Another key finding of the study is that the responses observed in these patients were durable, Boorjian reports.
Targeted Therapies Continue to Push the Field of EGFRm Lung Cancer Forward
December 6th 2023In an interview with Targeted Oncology, Edward B. Garon, MD, MS, discussed the ever-changing treatment landscape for EGFR-mutated lung cancer, as well as the unmet needs and potential next steps for research in this space.
Read More
Updated Trials at ESMO Reveal New Frontline Combo in Urothelial Carcinoma
December 2nd 2023Findings presented during the 2023 ESMO Annual Meeting have demonstrated a new combination of targeted therapies offering clinicians and patients renewed hope in this difficult to treat cancer type.
Read More